PCR Corp
St. Petersburg, Florida, 33702, United States
NCT Number: NCT04510675
The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
St. Petersburg, Florida, 33702, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Omeza Collagen Matrix
Occlusive Patch of 0.9% sodium chloride, NaCl
Time frame: 24, 48, 72, and 96 Hours
Erythema is evaluated during the challenge phase based on a numeric scale from 0 - 3 (0: No visible reaction, +: Slight/patchy, 1: Mild, 2: Moderate, 3: Strong). A score of 1, 2, or 3 indicates dermal sensitization.
Time frame: 6 weeks
The secondary outcome measure is the number of adverse events deemed related to the test article or the study.
Omeza, LLC
Industry
A 6-Week, Randomized, Evaluator-Blinded, In Vivo Within Subject Repeat Test to Evaluate the Irritation and Sensitization Potential of Omeza Collagen Matrix in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04498676
Erythema, Pathological Conditions, Signs and Symptoms
New City, New York, United States
View Trial DetailsNCT07725900
Dry Skin, Erythema
Semarang, Central Java, Indonesia
View Trial DetailsNCT07479004
Dermatitis, Dermatitis, Contact
Banská Bystrica, Slovakia
View Trial DetailsNCT06369675
Erythema, Pathological Conditions, Signs and Symptoms
Fair Lawn, New Jersey, United States
View Trial Details